Functional and multi-omic aging rejuvenation with GLP-1R agonism

Author:

Huang Junzhe,Kwok Andrew J.ORCID,Li Jason Chak Yan,Chiu Clement Lek Hin,Ip Bonaventure Y.,Tung Lok Yi,Zheng Xianyi,Chow Hoi Tung,Lo Michelle P. S.,Li ZhongqiORCID,Chan Roy C. H.,Lin Nenghan,Wang Ziyu,Wang Manyu,Yan Leo Y. C.,Chan Danny C. W.,Wu William K. K.ORCID,Chow Kim Hei-ManORCID,Lin Wei-Jye,Tang Yamei,Ng Billy Wai-LungORCID,Wong Sunny H.ORCID,Leung Thomas W.ORCID,Mok Vincent C. T.,Ko HoORCID

Abstract

AbstractIdentifying readily implementable methods that can effectively counteract aging is urgently needed for tackling age-related degenerative disorders. Here, we conducted functional assessments and deep molecular phenotyping in the aging mouse to demonstrate that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment attenuates body-wide age-related changes. Apart from improvements in physical and cognitive performance, the age-counteracting effects are prominently evident at multiple omic levels. These span the transcriptomes and DNA methylomes of various tissues, organs and circulating white blood cells, as well as the plasma metabolome. Importantly, the beneficial effects are specific to aged mice, not young adults, and are achieved with a low dosage of GLP-1RA which has a negligible impact on food consumption and body weight. The molecular rejuvenation effects exhibit organ-specific characteristics, which are generally heavily dependent on hypothalamic GLP-1R. We benchmarked the GLP-1RA age-counteracting effects against those of mTOR inhibition, a well-established anti-aging intervention, observing a strong resemblance across the two strategies. Our findings have broad implications for understanding the mechanistic basis of the clinically observed pleiotropic effects of GLP-1RAs, the design of intervention trials for age-related diseases, and the development of anti-aging-based therapeutics.

Publisher

Cold Spring Harbor Laboratory

Reference99 articles.

1. Targeting the biology of aging with mTOR inhibitors. Nat;Aging,2023

2. Kaeberlein, M. & Galvan, V . Rapamycin and Alzheimer’s disease: Time for a clinical trial? Sci. Transl. Med. 11, (2019).

3. Cellular senescence and senolytics: the path to the clinic;Nat. Med,2022

4. Strategies for targeting senescent cells in human disease. Nat;Aging,2021

5. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3